Yes and they had the same amount of patients as planned originally for the treatment arm, and were short on the placebo arm. There are a lot of potential explanations for that circumstance. I find it interesting to read the PIP approval, where you see the approval as describing the 2 different trials for nGBM and rGBM as single arm trials and of course the company says they will be using the same external control arm protocol they used in their main trial.
News 
Market Data 
Discover 
